The early diagnosis of lung cancer has become the focus of clinical attention, with the incidence and mortality of lung cancer increasing. Aberrant DNA methylation occurs in the primary stage of lung cancer, then the methylation degree can be changed dynamically due to the progress and the treatment of lung cancer. To date, a growing number of studies have reported that special gene methylation exploits in the clinical diagnosis, curative effect monitoring, and prognosis evaluation of lung cancer. Meanwhile, clinical trials about DNA methyltransferase inhibitors for lung cancer therapy are also underway. It is worth looking forward that detecting aberrant DNA methylation helps diagnose and treat lung cancer.
随着肺癌发病率与死亡率的增加,肺癌的早期诊断愈发成为临床诊疗关注的重点。DNA异常甲基化发生在肺癌早期,并随着疾病的进展及治疗动态变化。迄今为止,越来越多的研究报道特异性基因异常甲基化在肺癌诊断、疗效监测及预后评估方面的应用,同时DNA甲基转移酶抑制剂应用于肺癌治疗的临床试验也正在进行。DNA异常甲基化检测助力肺癌诊疗值得期待。.